Published online Jan 27, 2022. doi: 10.4254/wjh.v14.i1.209
Peer-review started: October 7, 2021
First decision: December 2, 2021
Revised: December 3, 2021
Accepted: December 23, 2021
Article in press: December 23, 2021
Published online: January 27, 2022
Processing time: 105 Days and 19.8 Hours
Hepatic resection has become the preferred treatment of choice for colorectal liver metastasis (CLM) patients.
To identify the prognostic factors and to formulate a new scoring system for management of CLM.
Clinicopathologic and long-term survival data were analyzed to identify the significant predictors of survival by univariate and multivariate analyses with the Cox model. A clinical score was constructed based on the analysis results.
Three factors of worse overall survival were identified in the multivariate analysis. They were number of liver metastases ≥ 5, size of the largest liver lesion ≥ 4 cm, and the presence of nodal metastasis from the primary tumor. These three factors were chosen as criteria for a clinical risk score for overall survival. The clinical score highly correlated with median overall survival and 5-year survival (P = 0.002).
Priority over surgical resection should be given to the lowest score groups, and alternative oncological treatment should be considered in patients with the highest score.
Core Tip: Using multivariate analysis with the Cox model, we identified three criteria-number of liver metastases ≥ 5, size of the largest liver lesion ≥ 4 cm, and the presence of nodal metastasis from the primary tumor-for a new clinical scoring system. This new clinical score highly correlated with median overall survival and 5-year survival. We propose to use this score to formulate cancer-specific treatment for the patients. Priority over surgical resection should be given to the lowest score groups, and alternative oncological treatment should be considered in patients with the highest score.